StreetInsider.com News Articles

FDA grants fast track status to Liquidia's Yutrepia for rare condition

Thu, 03 Sep 2026 07:30:44 -0400

Liquidia Corporation (Nasdaq: LQDA) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug Yutrepia (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis, known as SSc-RP.

Systemic sclerosis is a rare, chronic autoimmune disease, and Raynaud's phenomenon affects up to 90% of SSc patients, causing recurrent vasospastic episodes that produce pain, numbness, and color changes in the fingers and toes. The condition can progress to digital ischemic ulcers in an estimated 40% to 60% of patients and, in recurring cases, digital amputation. No therapy is currently approved in the U.S.

FDA grants fast track status to Liquidia's Yutrepia for rare condition

Thu, 03 Sep 2026 07:30:44 -0400

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

Thu, 03 Sep 2026 07:30:00 -0400

Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients
No therapy is currently approved in the U.S. to treat SSc-RP and management options are limited and often inadequate for patients with more severe disease
Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026

MORRISVILLE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

Thu, 03 Sep 2026 07:30:00 -0400

Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients
No therapy is currently approved in the U.S. to treat SSc-RP and management options are limited and often inadequate for patients with more severe disease
Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026

MORRISVILLE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

Wed, 02 Sep 2026 08:30:00 -0400

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.

Dr. Rajeev Saggar, M.D., Chief Medical Officer of Liquidia, said: “These presentations represent important steps in building the evidence around our inhaled treprostinil programs, which have the potential to meaningfully change the treatment experience for people living with pulmonary hypertension with interstitial

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

Wed, 02 Sep 2026 08:30:00 -0400

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

Tue, 01 Sep 2026 08:30:00 -0400

MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company’s business in a fireside chat at the Wells Fargo 21^st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET.

Access to this event will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

Tue, 01 Sep 2026 08:30:00 -0400

Form 4 Liquidia Corp For: Aug 21 Filed by: Adair Jason

Tue, 25 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26975171.html

Form 4 Liquidia Corp For: Aug 21 Filed by: Adair Jason

Tue, 25 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26975171.html

Form 144 Liquidia Corp Filed by: Adair Jason

Fri, 21 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26961924.html

Form 144 Liquidia Corp Filed by: Adair Jason

Fri, 21 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26961924.html

Form 4 Liquidia Corp For: Aug 19 Filed by: Rielly-Gauvin Katherine

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961794.html

Form 4 Liquidia Corp For: Aug 19 Filed by: Rielly-Gauvin Katherine

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961794.html

Form 4 Liquidia Corp For: Aug 17 Filed by: Saggar Rajeev

Wed, 19 Aug 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260819/26951393.html

Form 4 Liquidia Corp For: Aug 17 Filed by: Saggar Rajeev

Wed, 19 Aug 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260819/26951393.html

Form 144 Liquidia Corp Filed by: Rielly-Gauvin Katherine

Wed, 19 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260819/26950413.html

Form 144 Liquidia Corp Filed by: Rielly-Gauvin Katherine

Wed, 19 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260819/26950413.html

Form 144 Liquidia Corp Filed by: Saggar Rajeev

Wed, 19 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260819/26949992.html

Form 144 Liquidia Corp Filed by: Saggar Rajeev

Wed, 19 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260819/26949992.html

Form 144 Liquidia Corp Filed by: Saggar Rajeev

Mon, 17 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260817/26938785.html

Form 144 Liquidia Corp Filed by: Saggar Rajeev

Mon, 17 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260817/26938785.html

Form SCHEDULE 13G/A Liquidia Corp Filed by: Manning Paul B

Fri, 14 Aug 2026 19:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26933236.html

Form SCHEDULE 13G/A Liquidia Corp Filed by: Manning Paul B

Fri, 14 Aug 2026 19:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26933236.html

Liquidia Technologies (LQDA) PT Raised to $108 at Wells Fargo

Thu, 13 Aug 2026 08:42:14 -0400

Wells Fargo analyst Benjamin Burnett raised the price target on Liquidia Technologies (NASDAQ: LQDA) to $108.00 (from $62.00) while maintaining a Overweight rating.